Core Viewpoint - 基石药业-B (02616.HK) has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial application of CS2009, a PD-1/VEGF/CTLA-4 tri-specific antibody, for use in advanced solid tumors [1] Group 1: Clinical Trial Details - The Phase I study of CS2009 has provided significant confidence to the company, prompting the acceleration of the Phase II study [1] - The Phase II clinical trial will adopt a multi-cohort parallel expansion design, covering 15 monotherapy/combinational therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The Phase II clinical trial is currently actively enrolling participants in Australia, and the approval of the IND in China will further expedite the clinical development process [1] Group 2: Company Leadership - Dr. Yang Jianxin, CEO, President of R&D, and Executive Director of the company, expressed optimism regarding the therapeutic potential of CS2009 based on the initial data from the Phase I study [1]
基石药业-B(02616.HK)：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅱ期临床试验联合疗法IND在中国获批，深入探索三抗治疗潜力